This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Roth, M.
Right arrow Articles by Amrein, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roth, M.
Right arrow Articles by Amrein, R.

The British Journal of Psychiatry 168: 149-157 (1996)
© 1996 The Royal College of Psychiatrists

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial

M Roth, CQ Mountjoy and R Amrein
University of Cambridge Medical School.

BACKGROUND: The new reversible MAOl moclobemide was compared with placebo in the treatment of elderly patients with DSM-III diagnosis of dementia and/or of major depression. METHOD: Six hundred and ninety- four elderly patients with symptoms of depression and cognitive decline entered an international, multi-centre, double blind trial in which they were randomly allocated to treatment with either moclobemide 400 mg daily or placebo for 42 days. Five hundred and eleven patients met DSM-III criteria for dementia and were also depressed (DEM+D); 183 did not meet DSM-III criteria for dementia but met the criteria for DSM-III major depressive episode and also suffered from cognitive decline (MDE+CD). RESULTS: Analysis of the 17 and 24-item Hamilton Depression Scale scores showed that moclobemide, compared with placebo, produced significantly greater improvement in both the demented and depressed groups (P = 0.001 both diagnostic groups). There was an improvement in cognitive function as measured by the SCAG Factor 1 in moclobemide treated patients (P = 0.005 DEM+D; P = 0.02 MDE+CD). There was no evidence of decline in cognitive function as the result of treatment. Clinical global assessment of tolerance was 'excellent' and 'good' in 88% of the moclobemide and in 92% of the placebo treated patients. The proportion of patients discontinuing treatment prematurely was similar in both treatment groups. There were no significant differences in side- effects between treatment groups. There were no significant changes in vital signs, ECG or laboratory findings in either treatment group. There were no dietary restrictions and no report of any tyramine reaction. CONCLUSIONS: Moclobemide was shown to be a safe, well tolerated and effective antidepressant, which did not cause impairment of cognitive function in elderly patients with a DSM-III diagnosis of dementia and/or DSM-III major depression.


This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
C. G. Lyketsos, L. DelCampo, M. Steinberg, Q. Miles, C. D. Steele, C. Munro, A. S. Baker, J.-M. E. Sheppard, C. Frangakis, J. Brandt, et al.
Treating Depression in Alzheimer Disease: Efficacy and Safety of Sertraline Therapy, and the Benefits of Depression Reduction: The DIADS
Arch Gen Psychiatry, July 1, 2003; 60(7): 737 - 746.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Drugs for disruptive features in dementia
DTB, January 1, 2003; 41(1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study
JAMA, September 25, 2002; 288(12): 1475 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
G. C. Smith, D. M. Clarke, D. Handrinos, and D. P. McKenzie
Consultation-Liaison Psychiatrists' Use of Antidepressants in the Physically Ill
Psychosomatics, June 1, 2002; 43(3): 221 - 227.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al.
Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, May 8, 2001; 56(9): 1154 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. Mayeux and M. Sano
Treatment of Alzheimer's Disease
N. Engl. J. Med., November 25, 1999; 341(22): 1670 - 1679.
[Full Text] [PDF]

Home page
 BMJHome page
R C Baldwin, P. Haddad, R H McAllister-Williams, C. Gordon, M. G Livingston, and H. M Livingston
Antidepressants for old people
BMJ, September 25, 1999; 319(7213): 849b - 849.
[Full Text]

Home page
 BMJHome page
M. G Livingston and H. M Livingston
New antidepressants for old people?
BMJ, June 19, 1999; 318(7199): 1640 - 1641.
[Full Text]

Home page
 Stat Methods Med ResHome page
T. Johnson
Clinical trials in psychiatry: background and statistical perspective
Statistical Methods in Medical Research, June 1, 1998; 7(3): 209 - 234.
[Abstract] [PDF]